PSYCHEDELIC ALPHA

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond.

An Introduction to the Psychedelic Renaissance

40% of American adults report struggling with mental health or substance abuse disorders. Psychedelics may provide solutions to the global mental health and wellbeing crisis.

After decades of repression, psychedelic research is thriving.

Promising research has already resulted in FDA Breakthrough Therapy designations for psilocybin-assisted therapies aimed at treating depression, and MDMA-assisted psychotherapy for PTSD. Research on other ‘psychedelics’, including MDMA and LSD, is picking up pace with research centres at prestigious institutions—including Johns Hopkins and Imperial College London—driving a new wave of psychedelic research.

Decriminalisation and legalisation campaigns are succeeding.

In 2020 the U.S. state of Oregon voted to decriminalise psychedelics and legalise Psilocybin Therapy. Washington, D.C., home of the White House, also decriminalised psychedelics, with many other states and localities poised to follow suit. Canada’s Health Minister has granted exemptions to allow access to psilocybin-assisted psychotherapy, setting precedent for future efforts to expand access.

Significant clinical trial milestones on the horizon.

In a Phase 3 MDMA-assisted therapy for PTSD trial that published last year, 88% of participants responded to the treatment. The trial’s sponsor, MAPS, expects to seek FDA approval in or around 2024. Multiple trials of psilocybin for depression are in Phase 2 or entering Phase 3, and are indicating preliminary safety and efficacy.

Psychedelics have the potential to address depression anxiety addiction PTSD chronic pain

Welcome to the Psychedelic Renaissance.

The Psychedelic Renaissance in Context

Today’s psychedelic renaissance benefits from a rich legacy of psychedelic research and usage dating back to pre-historic times.

The extensive psychedelic research and experimentation of the 1950s and ’60s represents a significant endowment, with today’s researchers taking up the torch.

1943

Albert Hofmann intentionally ingests LSD, experiencing the effects while cycling home. “Bicycle Day” is coined.

mid 1960s – 1971

Psychedelics criminalised, with Nixon declaring a War on Drugs in 1971 and a UN Convention following suit.

~10,000 BCE

Psychedelic iconography, such as mushrooms, appear in etched murals dating 10,000 BCE.

1950s and ’60s

Fertile decades for psychedelics research and experimentation, particularly in the U.S.

21st Century

Psychedelic renaissance emerges, with a return to human studies of psychedelics and decriminalisation campaigns.

Our Latest Analysis

Psychedelic Bulletin #125: New Data Boosts Spravato’s Case; Bipartisan Breakthrough Therapies Act; Berkeley Could Decrim. Psychedelics; DEA Increases Production Quotas

This week: New Phase 3b data boosts Spravato amid payer hesitancy; Berkeley Health Commission votes to move psychedelics decrim. resolution to City Council; our analysis of the rescheduling clauses in the Breakthrough Therapies Act; and much more…

Psychedelic Bulletin #124: MAPS Wraps Second Phase 3 MDMA Trial; Preparing for atai’s PCN-101 Results; Tactogen Launches Community Funding Round

This week: MAPS PBC finished its second Phase 3 trial of MDMA-AT for PTSD; we contextualise atai’s upcoming PCN-101 (R-Ketamine) readout; Tactogen launches crowdfunding round; and much more…

Psychedelic Bulletin #123: Colorado Psilocybin Therapy Prop Passes While Swathes of Oregon Opt-out; Sensorium Closes $30m Series A

This week: Colorado’s Prop 122 passes, decriminalising a number of psychedelics and establishing regulated psilocybin therapy; many Oregon counties opt-out; Sensorium closes $30m Series A round; and much more…

Receive Our Updates

Join our Newsletter

Psychedelic insights, commentary and analysis delivered to your inbox, including our weekly Bulletin.

Follow Us on Twitter

Join us on Twitter where we share the latest news and analysis, covering the entire psychedelic space.

Axios Logo
Business Insider logo grey
New York Times
Mother Jones Logo
Rolling Stone Logo
Finimize logo grey
Vice Logo